Early-phase clinical trial data indicate notable activity in heavily pretreated patients with RRMM, including those with triple-class-refractory disease, together with a tolerable and manageable safety profile. This review summarizes current preclinical and clinical findings with mezigdo...
Paul Richardson, MD, discusses the safety and efficacy findings from the CC-92480-MM-002 trial of mezigdomide with dexamethasone and daratumumab or elotuzumab in patients with relapsed/refractory multiple myeloma. Video Player is loading.This is a modal window. ...
Paul Richardson, MD, discusses the background and design of the CC-92480-MM-002 trial in multiple myeloma.
Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial 来自 dx.doi.org 喜欢 0 阅读量: 1 ...
16 However, nearly 40% of patients on the trial developed mutations in MEN1, which encodes menin.17 These mutations affect menin inhibitor binding to menin without displacing KMT2A, thereby markedly diminishing menin inhibitor responses. Consequently, rationally chosen combination therapy that ...
David Samuel Dicapua Siegel, MD, discusses preliminary findings from the phase 1/2 CA057-003 trial of mezigdomide in relapsed/refractory multiple myeloma. Video Player is loading. This is a modal window. This video is either unavailable or not supported in this browser Error Code: ...
Mezigdomide (CC-92480), a potent, novel cereblon E3 ligase modulator (CELMoD), combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): preliminary results from the dose-expansion phase of the CC-92480-MM-001 trial. Bl...
(Tazverik), and dexamethasone demonstrated early signals of activity and a tolerable safety profile in patients with highly refractory multiple myeloma, according to preliminary findings from the phase 1b/2a CA057-003 trial (NCT05372354), presented at the 21st International Myeloma Soc...
Clinical Trial 分子量 567.61 Formula C32H30FN5O4 CAS 号 2259648-80-9 运输条件 Room temperature in continental US; may vary elsewhere. 储存方式 Powder-20°C 3 years 4°C 2 years In solvent-80°C 6 months -20°C 1 month 溶解性数据 In Vitro: DMSO : 5 mg/mL (8.81 mM; ultraso...
CAR T in Early R/R MM: Advances in Ide-Cel From the KarMMa-3 Trial Dr Lin on Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma Dr Phull on Real-World vs Trial Data for CAR T-Cell Therapy in R/R Multiple Myeloma Cilta-Cel in Early R/R MM: Evolving CAR T Data from CARTITUDE...